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BACKGROUND
Control of risk factors and enhancement of protective
factors are the keystones to avoid hemorrhagic stroke
[1]. Smoking cessation is important for the prevention
of this illness [2]. The use of pharmacological agents
to control tobacco addition is irrefutable [3,4].
Unfortunately, first-line therapies are not always
safety [4,5]. Some of these drugs are able to induce
cardiovascular adverse events. Here, we present a
case of a hypertensive patient with a hemorrhagic
stroke due to drug-drug interaction, by the addition
of an atypical antidepressant for smoking cessation to
her well control antihypertensive treatment.
CASE REPORT
A 44-year-old woman was referred to the hospital
because of left frontal headache, nausea and vomit-
ing. On admission, the patient was conscious and had
a blood pressure of 200/100 mm Hg. The neurologi-
cal examination revealed a mild motor aphasia, a left
hemiparesis and a slight neck retraction. The patient
was diagnosed 10 years ago of essential hypertension
and treated with bisoprolol (10 mg per day). She had
also been a smoker for 25 cigarettes per day, but she
had discount smoking approximately 2 months ago.
10 days before she stopped smoking she began to be
treated with bupropion (150 mg per day). The labo-
ratory studies were all normal, except for a high plas-
ma glucose levels (200 mg/dl). Computerized tomog-
raphy, an established tool for the diagnosis of stroke
[6], demonstrated different signs of acute haemor-
rhage stroke (Figure 1).
DISCUSSION
Per se smoking and hypertension are established risk
factors for hemorrhagic stroke in men [2,7]. In both
cases pharmacological agents could be used to
favour smoking cessation [4] and reduce blood pres-
sure levels [8]. However, the combination therapy
using an antihypertensive drugs and antidepressants
for to treat both diseases at the same time may not
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patients are hypertensives and well treated with specific drugs. This drug is unable to reduce cardiovascular risks
in those patients.
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be safer, as we shown in this case report, and not
necessary could be related to a drug-drug interaction
on CYP2D6 metabolism [9,10].
It is certainly that the rise in blood pressure was the
potential mediator that caused the rupture of brain
arteries and produced the hemorrhagic stroke in this
young woman. In our case report the neurovisualiza-
tion confirmed the brain damage. Nevertheless, the
woman was previously well treated with bisoprolol, a
selective β1-adrenoceptor antagonist devoid of par-
tial agonist activity that is often used for the treat-
ment of hypertension [11]. Perhaps, the secondary
addition of bupropion chronically to the beta-blocker
could induce the hypertensive emergency.
Bupropion is an atypical antidepressant using for
smoking cessation [5,12,13]. Experimental data have
evidenced that this drug is a relatively weak inhibitor
of norepinephrine and dopamine reuptake mecha-
nisms. This drug has also an indirect role on serotonin
(5-HT) neuronal elements [14]. Bupropion is able to
increase plasma norepinephrine levels in rats [15], an
important mechanism to develop hypertension and
favour stroke [8]. Recently data in healthy male sub-
jects demonstrate that the main mechanism of action
of bupropion is to enhance synaptic availability of nor-
epinephrine by increasing its release [16].
For several authors, hypertension is considered as a
confounder factor between the possible connexion of
the use of antidepressants and stroke [17]. In gener-
al, pharmaceutical products containing bupropion
are not related to an increase risk for stroke,
although several reports evidence an exacerbation in
baseline hypertension [18,19]. We must to observe
that in hypertension there is an increase in the densi-
ty of sympathetic innervation in human and a faulty
norepinephrine reuptake [20]. If we give bupropion
chronically in combination with a selective β1-
adrenoceptor antagonist, like bisoprolol, we did not
inhibit all the vascular effects of norepinephrine, a
neurotransmitter of the sympathetic nervous system
that stimuli different subtypes of α- and β-adreno-
ceptors. In the vast majority of vascular tissues
(arteries and veins), α1-adrenoceptors-mediated
vasoconstriction and α2-adrenoceptors-mediated the
neural complex system regulating cardiovascular
function [21]. A chronic increase in norepinephrine
levels could evoke more increase in vascular tone
and an overactivation of somatodendritic α2-adreno-
ceptors. Desensitization of α2-adrenoceptors, sec-
ondary to an increased exposure to the endogenous
agonist ligand norepinephrine or prolonged occupa-
tion of the norepinephrine transporter [22,23], could
produce more hypertension. It is not yet known
whether all α-adrenoceptor subtypes are predomi-
nantly implicated. Perhaps, in this case report the
association between bupropion and bisoprolol, a
drug-drug interaction would be the cause of the exa-
cerbation of the hypertension and the production of
the hemorrhagic stroke that could never be mention.
CONCLUSIONS
Drug therapy is a logical approached. A rational
therapeutic decision includes selecting patients and
specific drugs. Perhaps, bupropion, an atypical anti-
depressant, may not be useful for smoking cessation
if patients are hypertensives. This drug is unable to
reduce cardiovascular risks in those treated-patients.
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Figure 1. A brain imaging (computerized tomography) of a 44-years-
-old woman with hemorrhagic stroke due to a drug-drug
interaction. The arrow shows the right part of the imaging.
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